Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.44 |
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6126769 | 0.90 | HCRTR1 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL14979634 | 0.86 | PTGES (0.37) | HCRTR1HCRTR2PTGES | |
| SCHEMBL14979723 | 0.81 | TSHR (0.40) | HCRTR1HCRTR2PTGESMEN1LMNA | |
| SCHEMBL6126763 | 0.79 | TSHR (0.40) | HCRTR1HCRTR2PTGESMEN1LMNA | |
| SCHEMBL8752289 | 0.79 | TSHR (0.40) | HCRTR1HCRTR2PTGESMEN1LMNA | |
| SCHEMBL15033818 | 0.79 | CYP3A4 (0.56) | — | |
| SCHEMBL15072183 | 0.79 | CYP3A4 (0.56) | — | |
| SCHEMBL14979729 | 0.79 | CYP3A4 (0.56) | — | |
| SCHEMBL15052694 | 0.79 | CYP3A4 (0.56) | — | |
| SCHEMBL14979663 | 0.79 | CYP3A4 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3778606-A2 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10807990-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-10800789-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-20200071337-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190276468-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-09-12 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3431477-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180186806-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130309196-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2013-11-21 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013075029-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071337-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885PTGES 2945/4885 |
| US-20130309196-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885PTGES 2945/4885 |
| US-20180186806-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885PTGES 2945/4885 |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885PTGES 2945/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | HCRTR1 4298/4885HCRTR2 4654/4885PTGES 2784/4885 |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885PTGES 2945/4885 |
| US-20190276468-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885PTGES 2945/4885 |
| US-10807990-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885PTGES 2945/4885 |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885PTGES 2945/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HCRTR1 4298/4885HCRTR2 4654/4885PTGES 2784/4885 |
| US-10800789-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885PTGES 2945/4885 |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885PTGES 2945/4885 |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | HCRTR1 4632/4885HCRTR2 4795/4885PTGES 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.